实时催化剂监控

Best fit for Edge Computing & Memory preference: 89% growth, EBITDA positive, reasonable 4.2x sales, and direct exposure to AI networking bottlenecks with durable hyperscaler demand.

Clean Defense & Hard Tech fit with real revenue, 21% growth, EBITDA positive operations, and backlog-backed modernization demand without extreme valuation.

Among Biotech 2.0 names it has meaningful commercial/partner revenue, strong growth, catalyst score above 70, low dilution risk, and >18 months runway.

Commercial-stage biotech with 64% growth, acceptable 5.3x sales, low modeled dilution risk, and a credible path toward breakeven rather than pure binary science.

AI Energy Infra exposure with massive revenue base, EBITDA positivity, very low 0.3x sales, and visible cash generation tied to tightening power markets.

Another pragmatic AI power beneficiary with EBITDA support, low 0.5x sales, and merchant/nuclear generation leverage to data-center load growth.

Strong 72% growth and defense/hard-tech tailwinds with improving scale economics; valuation is richer, but revenue durability is better than many theme names.

Profitable semi equipment/process control name with real revenue, 23% growth, and exposure to advanced packaging/memory spending rather than speculative edge themes.

Profitable unmanned systems leader with 33% growth and direct exposure to one of the hottest spending pockets in defense, backed by procurement visibility.

Higher-risk biotech platform, but revenue growth is exceptional, runway exceeds 18 months, dilution risk is moderate, and AI-enabled partnership revenue adds some durability.

Defense AI software remains one of the strongest thematic tapes, with profitability, 30% growth, and headline-driven contract momentum supporting continued relative strength despite premium valuation.

Defense-tech supercycle plus launch/space systems narrative can keep the rerating alive as geopolitics support security-premium multiples.

Combat validation and procurement urgency keep unmanned systems in the market’s hot zone; AVAV has both growth and profitability to sustain attention.

Autonomous defense systems and target drone programs give KTOS a strong under-owned angle within the hot defense complex.

AI networking remains a scarce-infrastructure trade; CRDO combines hot exposure with unusually solid fundamentals for the theme.

AI power demand is one of the market’s most credible second-derivative themes, and NRG offers torque if investors rotate from expensive AI compute into power beneficiaries.

Merchant power/nuclear exposure gives VST direct leverage to the AI electricity scarcity narrative at a still-compressed sales multiple.

Biotech 2.0 rotation favors commercializing, better-funded platform stories; CRSP has enough revenue and runway to participate if the group rerates.

Commercial-stage biotech with visible uptake can outperform in a Biotech 2.0 tape that rewards execution over binary stories.

AI-native biotech remains a strong narrative pocket; RXRX can attract momentum if platform/partner milestones reinforce revenue durability.

CRSP remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

RUN remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

RKLB remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

FLNC remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

PLTR remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

NRG remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

CRDO remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

ARQT remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

VST remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

RXRX remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

AVAV remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

BBAI remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

KTOS remains on the shortlist because revenue is real, valuation is compressed, and the sector still has attention.

PLTR has an earnings window within the monitored horizon.

NRG has an earnings window within the monitored horizon.

AVAV has an earnings window within the monitored horizon.

CRDO has an earnings window within the monitored horizon.

VST has an earnings window within the monitored horizon.

RKLB has an earnings window within the monitored horizon.

RXRX has an earnings window within the monitored horizon.

SDGR has an earnings window within the monitored horizon.

ONTO has an earnings window within the monitored horizon.

NVTS has an earnings window within the monitored horizon.

EXAS has an earnings window within the monitored horizon.

SOUN has an earnings window within the monitored horizon.

STEM has an earnings window within the monitored horizon.

ENPH has an earnings window within the monitored horizon.

KTOS has an earnings window within the monitored horizon.

ARQT has an earnings window within the monitored horizon.

NOVA has an earnings window within the monitored horizon.

BBAI has an earnings window within the monitored horizon.

WOLF has an earnings window within the monitored horizon.

FLNC has an earnings window within the monitored horizon.

NTLA has an earnings window within the monitored horizon.

QUBT has an earnings window within the monitored horizon.

RUN has an earnings window within the monitored horizon.

CRSP has an earnings window within the monitored horizon.